Ticagrelor was more effective than clopidogrel in acute coronary syndromes with planned invasive treatment

Brophy, James M.
May 2010
ACP Journal Club;5/18/2010, Vol. 152 Issue 5, p3
Academic Journal
The article reports on a study that discusses safety and efficiency of ticagrelor and clopidogrel in patients with planned invasive management of an acute coronary syndrome (ACS). As stated, based on a secondary analysis of randomized controlled trial, thousands of patients were admitted for an ACS with an invasive management strategy plan. However it concludes that ticagrelor was more effective in patients with ACS and planned invasive treatment rather than clopidogrel.


Related Articles

  • Ticagrelor Superior to Clopidogrel in Reducing MI, Stroke, and CV Death in ACS (PLATO).  // MD Conference Express;Nov2009, p16 

    The article highlights results of the study Platelet Inhibition and Patient Outcomes (PLATO), presented by Professor Lars Wallentin of Uppsala Clinical Research Center in Uppsala, Sweden. It is stressed that the result of the clinical trial found out that in patients with acute coronary syndrome...

  • Results of the TRIGGER-PCI trial reported at TCT 2011.  // Biomedical Market Newsletter;11/14/2011, Vol. 21, p784 

    The article discusses the results of the TRIGGER-PCI clinical trial at the 23rd annual Transcatheter Cardiovascular Therapeutics symposium, sponsored by the Cardiovascular Research Foundation. The efficacy of prasugrel to clopidogrel following percuataneous coronary intervention was compared. An...

  • First Large-Scale Platelet Function Evaluation in an Acute Coronary Syndrome Trial: The Trilogy ACS-Platelet Function Substudy. Vinall, Phil // MD Conference Express;Dec2012, p14 

    The article discusses the findings from the A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects (TRILOGY ACS) trial by Paul Gurbel. The TRILOGY ACS trial compares the effectivess of prasugrel and clopidogrel in patients with unstable angina (UA) or non-ST segment...

  • Serelaxin as a Novel Treatment for Acute Heart Failure: Results of the RELAX-AHF Trial. Vinall, Phil // MD Conference Express;Dec2012, p22 

    The article discusses the findings form the Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure trial by John R. Teerlink. The study aims to test the efficacy and safety of serelaxin, a recombinant version of human relaxin-2, in patients with acute heart failure (AHF). It...

  • American Heart Association.  // BioWorld Today;11/17/2009, Vol. 20 Issue 222, p10 

    This article deals with the results obtained by Eli Lilly and Co. from a study of patients with type II diabetes mellitus and coronary artery disease who received prasugrel and clopidogrel. Particular focus is given to their dosing regimen. According to the study, prasugrel therapy led to a...

  • Results from CURRENT-OASIS 7.  // MD Conference Express;Nov2009, p15 

    The article highlights findings of the Clopidogrel optimal loading dose Usage to Reduce Recurrent EveNTs-Organization to Assess Strategies in Ischemic Syndromes (CURRENT-OASIS 7) trial, presented by Professor Shamir Mehta of McMaster Clinic in Hamilton, Ontario, Canada. It is stressed that the...

  • JUPITER Subgroup Analysis Provides Convincing Evidence for Statin Therapy as Primary Prevention for CV Events in Older Individuals.  // MD Conference Express;Nov2009, p22 

    The article highlights the findings of JUPITER subgroup analysis trial, presented by Robert Glynn of Brigham's and Women's Hospital in Boston, Massachusetts. It is stressed that the clinical trial was aimed to evaluate the effectiveness of rosuvastatin and placebo in the reduction of major...

  • Did AIM-HIGH Start Too Low? Toth, Peter P. // Cardiology Today;Jan2012 Supplement, p10 

    The article discusses the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes trial, which compared the efficacy of statin monotherapy with statin-niacin combination therapy in patients with established coronary artery disease.

  • Statins cut cardiovascular events by a quarter in people with diabetes. Mayor, Susan // BMJ: British Medical Journal (International Edition);6/21/2003, Vol. 326 Issue 7403, p1348 

    Statin treatment reduces major coronary events, revascularisations, and stroke by nearly a quarter in people with diabetes regardless of whether they have occlusive arterial disease or raised cholesterol. The Medical Research Council/British Heart Foundation heart protection study randomly...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics